J&J says IMAAVY shows sustained disease control through two years in adolescent myasthenia gravis study

By Public Technologies
  • Johnson & Johnson announced new long-term data on IMAAVY for generalized myasthenia gravis, scheduled for presentation at AANEM 2026.
  • A Phase 2/3 adolescent extension study showed disease control and functional improvement held up through two years, with some steroid reduction.
  • A retrospective survey of adult treatment switches found inconsistent symptom control was the top reason to stop prior advanced therapy.
  • Clinicians reported most patients improved after moving to IMAAVY, with many also cutting prednisone use.
  • IMAAVY is positioned as an FcRn blocker with pediatric authorization in the U.S. and Europe for certain antibody-positive gMG patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609290803PR_NEWS_USPR_____NY58035) on September 29, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk